MX2023014944A - Profarmacos de desoxinucleosidos para el tratamiento de enfermedades mitocondriales causadas por grupos de nucleosidos desequilibrados. - Google Patents

Profarmacos de desoxinucleosidos para el tratamiento de enfermedades mitocondriales causadas por grupos de nucleosidos desequilibrados.

Info

Publication number
MX2023014944A
MX2023014944A MX2023014944A MX2023014944A MX2023014944A MX 2023014944 A MX2023014944 A MX 2023014944A MX 2023014944 A MX2023014944 A MX 2023014944A MX 2023014944 A MX2023014944 A MX 2023014944A MX 2023014944 A MX2023014944 A MX 2023014944A
Authority
MX
Mexico
Prior art keywords
prodrugs
treatment
deoxynucleosides
diseases caused
mitochondrial diseases
Prior art date
Application number
MX2023014944A
Other languages
English (en)
Spanish (es)
Inventor
Daniel Dipietro
Original Assignee
Zogenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zogenix Inc filed Critical Zogenix Inc
Publication of MX2023014944A publication Critical patent/MX2023014944A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
MX2023014944A 2021-06-18 2022-06-15 Profarmacos de desoxinucleosidos para el tratamiento de enfermedades mitocondriales causadas por grupos de nucleosidos desequilibrados. MX2023014944A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163212468P 2021-06-18 2021-06-18
PCT/US2022/033654 WO2022266237A1 (en) 2021-06-18 2022-06-15 Prodrugs of deoxynucleosides for treatment of mitochondrial diseases caused by unbalanced nucleotide pools

Publications (1)

Publication Number Publication Date
MX2023014944A true MX2023014944A (es) 2024-04-25

Family

ID=84526701

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023014944A MX2023014944A (es) 2021-06-18 2022-06-15 Profarmacos de desoxinucleosidos para el tratamiento de enfermedades mitocondriales causadas por grupos de nucleosidos desequilibrados.

Country Status (9)

Country Link
US (2) US20230000890A1 (cg-RX-API-DMAC7.html)
EP (1) EP4355336A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024522783A (cg-RX-API-DMAC7.html)
CN (1) CN117500510A (cg-RX-API-DMAC7.html)
AU (1) AU2022291783A1 (cg-RX-API-DMAC7.html)
CA (1) CA3222484A1 (cg-RX-API-DMAC7.html)
IL (1) IL309421A (cg-RX-API-DMAC7.html)
MX (1) MX2023014944A (cg-RX-API-DMAC7.html)
WO (1) WO2022266237A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022204555A1 (en) * 2021-03-26 2022-09-29 Zogenix Mds, Inc. Aqueous solutions containing purines and pyrimidines and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10292996B2 (en) * 2015-03-26 2019-05-21 The Trustees Of Columbia University In The City Of New York Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome
WO2016205671A1 (en) * 2015-06-17 2016-12-22 The Trustees Of Columbia University In The City Of New York Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial dna depletion syndromes
EP3377512A4 (en) * 2015-11-16 2019-09-18 Ichorion Therapeutics, Inc. Nucleic Acid PRODRUGS
IL277725B2 (en) * 2018-04-12 2024-02-01 Modis Therapeutics Inc Pro-drugs of deoxynucleosides for the treatment of diseases resulting from an imbalance in the nucleotide reserves

Also Published As

Publication number Publication date
US20230000890A1 (en) 2023-01-05
WO2022266237A1 (en) 2022-12-22
CN117500510A (zh) 2024-02-02
EP4355336A1 (en) 2024-04-24
AU2022291783A1 (en) 2024-02-01
CA3222484A1 (en) 2022-12-22
US20250049836A1 (en) 2025-02-13
IL309421A (en) 2024-02-01
JP2024522783A (ja) 2024-06-21
EP4355336A4 (en) 2025-05-07

Similar Documents

Publication Publication Date Title
MX388140B (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
JOP20190076A1 (ar) مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
PH12020551332A1 (en) Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
EA201990665A1 (ru) Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака
PH12018500121A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
EA201790658A1 (ru) Производные диарилмочевины в качестве ингибиторов киназы p38
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
MX2020010999A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos.
MY183036A (en) Amino-triazolopyridine compounds and their use in treating cancer
EA201590391A1 (ru) Пиразолилмочевины в качестве ингибиторов киназы
PH12018500040A1 (en) Indazole and azaindazole compounds as irak-4 inhibitors
EA201792619A1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы
MX2021007260A (es) Inhibidores de la vía de cinasa janus 1 (jak1) para el tratamiento de enfermedades gastrointestinales.
EA201790122A1 (ru) Производные 2-h-индазола в качестве ингибиторов циклинзависимых киназ (cdk) и их терапевтическое применение
BR112016029041A8 (pt) uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico
MX2022002219A (es) Triazolopirimidinas como inhibidores de a2a/a2b.
MX393452B (es) Tratamiento de los trastornos depresivos.
EA201990109A1 (ru) Митохондриальные ингибиторы для лечения пролиферативных нарушений
MX2018012275A (es) Inhibidores de quinasa.
MX2018005872A (es) Profarmacos de acido nucleico.
CL2020003070A1 (es) Selección y uso de bacterias de apoyo de melatonina para reducir el cólico infantil
MX2018013885A (es) Métodos de tratamiento de enfermedades asociadas con células linfoides innatas del grupo 3 (cli3).
EA201990940A1 (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
WO2018229551A3 (en) METHODS OF TREATING A DISORDER RELATED TO THE USE OF OPIOIDS
EA201990834A1 (ru) Пиримидиновые пролекарства для лечения вирусных инфекций и других заболеваний